Tamsulosina

Tamsulosin

Usi approvati

• Dutasteride and tamsulosin hydrochloride capsules are a combination of dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
• Limitations of Use: Dutasteride-containing products, including dutasteride and tamsulosin hydrochloride capsules, are not approved for the prevention of prostate cancer.

Forme e dosaggi

• Dutasteride and tamsulosin hydrochloride capsules, USP containing 0.5 mg dutasteride and 0.4 mg tamsulosin hydrochloride, are size "00" hard shell-capsules with opaque orange cap imprinted with 'DTT'...

Come si assume

• The recommended dosage of dutasteride and tamsulosin hydrochloride capsules is 1 capsule (0.5 mg dutasteride and 0.4 mg tamsulosin hydrochloride) taken once daily approximately 30 minutes after the same meal each day.
• The capsules should be swallowed whole and not chewed or opened.
• Contact with the contents of the dutasteride and tamsulosin hydrochloride capsule may result in irritation of the oropharyngeal mucosa.
• Take one capsule daily approximately 30 minutes after the same meal each day.

Non deve essere usato in caso di

• Dutasteride and tamsulosin hydrochloride capsules are contraindicated for use in: Pregnancy.
• Dutasteride use is contraindicated in females who are pregnant.
• In animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia.
• Therefore, dutasteride and tamsulosin hydrochloride capsules may cause fetal harm when administered to a pregnant female.

Interazioni

• There have been no drug interaction trials using dutasteride and tamsulosin hydrochloride.
• The following sections reflect information available for the individual components.

Avvertenze e precauzioni

• Orthostatic hypotension and/or syncope can occur. Advise patients of symptoms related to postural hypotension and to avoid situations where injury could result if syncope occurs.
• Do not use dutasteride and tamsulosin hydrochloride with other alpha-adrenergic antagonists, as this may increase the risk of hypotension.
• Dutasteride and tamsulosin hydrochloride reduces serum prostate-specific antigen (PSA) concentration by approximately 50%. However, any confirmed increase in PSA while on dutasteride and tamsulosin hydrochloride may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men.
• Do not use dutasteride and tamsulosin hydrochloride with strong inhibitors of cytochrome P450 (CYP) 3A4 (e.g., ketoconazole). Use caution in combination with moderate CYP3A4 inhibitors (e.g., erythromycin) or strong (e.g., paroxetine) or moderate CYP2D6 inhibitors, a combination of both CYP3A4 and CYP2D6 inhibitors, or known poor metabolizers of CYP2D6.
• Exercise caution with concomitant use of phosphodiesterase-5 (PDE-5) inhibitors, as this may increase the risk of hypotension.
• Drugs that contain dutasteride, including dutasteride and tamsulosin hydrochloride, may increase the risk of high-grade prostate cancer.
• Prior to initiating treatment with dutasteride and tamsulosin hydrochloride, consideration should be given to other urological conditions that may cause similar symptoms.
• Females who are pregnant or may be pregnant should not handle dutasteride and tamsulosin hydrochloride capsules due to potential risk to a male fetus.

Effetti indesiderati comuni

• most common adverse reactions, reported in ≥1% of subjects treated with coadministered dutasteride and tamsulosin are ejaculation disorders, impotence, decreased libido, dizziness, and breast disorders.
• most common adverse reactions reported in subjects receiving coadministered dutasteride and tamsulosin were impotence, decreased libido, breast disorders (including breast enlargement and tenderness), ejaculation disorders, and dizziness.
• most common adverse reaction in all treatment arms leading to trial withdrawal was erectile dysfunction (1% to 1.5%).

Gravidanza

Dutasteride and tamsulosin hydrochloride is contraindicated for use in pregnancy because it may cause harm to the male fetus. Dutasteride and tamsulosin hydrochloride is not indicated for use in females. Dutasteride, a component of dutasteride and tamsulosin hydrochloride, is a 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), a hormone necessary for normal development of male genitalia.

Meccanismo d'azione

Dutasteride and tamsulosin hydrochloride are a combination of 2 drugs with different mechanisms of action to improve symptoms in patients with BPH: dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an antagonist of alpha 1A -adrenoreceptors. Dutasteride Dutasteride inhibits the conversion of testosterone to DHT. DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland.

Titolare dell'autorizzazione:

Aurobindo Pharma Limited

Versione della scheda:

19 luglio 2024

Le sezioni qui sopra sono citate dalla scheda in lingua inglese, perché è quel documento a portare l'approvazione. Dove un'autorità europea pubblica le stesse informazioni in italiano, il link è tra le fonti. Non traduciamo da soli i testi regolatori: un errore di traduzione in una controindicazione sarebbe più pericoloso di una riga in un'altra lingua.

Questa sezione riporta le informazioni sul prodotto approvate. Il testo è condensato dalla sintesi dell'autorità stessa e il documento completo è linkato tra le fonti.